Pinoresinol diglucoside (PDG), an active component derived from Eucommia ulmoides, exhibits therapeutic effects against apoptosis, inflammation, and hypertrophy, etc. However, whether PDG plays a protective role in diabetic cardiomyopathy (DCM) is not fully elucidated. This study aimed to investigate the role and potential mechanism of PDG in DCM. The possible mechanism of PDG targeting DCM was identified by network pharmacology, bioinformatics, machine learning and molecular docking methods. The heart function of mice was evaluated using echocardiography. The pathological changes in the heart of mice were detected using H&E staining. Changes of Ca2+ fluorescence intensity values in H9c2 cells were assessed by confocal microscopy. Apoptosis was evaluated by TUNEL staining and flow cytometry. The expression of DCM-related genes and proteins, both in vivo and in vitro, was examined by qRT-PCR and Western blot. The results showed that PDG effectively improved the cardiac function and suppressed cardiac hypertrophy, inflammation, and cardiomyocyte apoptosis caused by DCM. Intriguingly, molecular docking results revealed that the therapeutic effect of PDG on DCM was associated with stromal interaction molecule 1 (STIM1), calcium release-activated calcium channel protein 1 (Orai1), and nuclear factor of activated T-cells 3 (NFAT3) signaling. Consistently, animal experiments results indicated that PDG significantly downregulated the expression of STIM1, Orai1, NFAT3 at the protein level, as well as the associated store-operated calcium entry (SOCE). Therefore, our findings revealed that PDG can alleviate cardiac hypertrophy, inflammation and apoptosis in DCM by downregulating the STIM1, Orai1, and NFAT3 signaling molecules. Thus, PDG may be a promising therapeutic candidate for treating DCM.
Declaration of competing interest
These authors have no conflict of interest to declare.
| [1] |
Zhao X, Liu S, Wang X, et al. Diabetic cardiomyopathy: clinical phenotype and practice. Front Endocrinol (Lausanne). 2022; 13:1032268. https://doi.org/10.3389/fendo.2022.1032268.
|
| [2] |
Huo JL, Feng Q, Pan S, et al. Diabetic cardiomyopathy: early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions. Cell Death Discov. 2023; 9(1):256. https://doi.org/10.1038/s41420—023—01553—4.
|
| [3] |
Li W, Liu X, Liu Z, et al. The signaling pathways of selected traditional Chinese medicine prescriptions and their metabolites in the treatment of diabetic cardiomyopathy: a review. Front Pharmacol. 2024; 15:1416403. https://doi.org/10.3389/fphar.2024.1416403.
|
| [4] |
Sohn P, McLaughlin MR, Krishnan P, et al. Stromal interaction molecule 1 maintains β—cell identity and function in female mice through preservation of G—protein—coupled estrogen receptor 1 signaling. Diabetes. 2023; 72(10):1433-1445. https://doi.org/10.2337/db22—0988.
|
| [5] |
Rosenberg P, Zhang H, Bryson VG, et al. SOCE in the cardiomyocyte: the secret is in the chambers. Pflugers Arch. 2021; 473(3):417-434. https://doi.org/10.1007/s00424—021—02540—3.
|
| [6] |
Stiber J, Hawkins A, Zhang ZS, et al. STIM1 signalling controls store—operated calcium entry required for development and contractile function in skeletal muscle. Nat Cell Biol. 2008; 10(6):688-697. https://doi.org/10.1038/ncb1731.
|
| [7] |
Luo X, Hojayev B, Jiang N, et al. STIM1—dependent store—operated Ca2+ entry is required for pathological cardiac hypertrophy. J Mol Cell Cardiol. 2012; 52(1):136-147. https://doi.org/10.1016/j.yjmcc.2011.11.003.
|
| [8] |
Pang Y, Hunton DL, Bounelis P, et al. Hyperglycemia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes. Diabetes. 2002; 51(12):3461-3467. https://doi.org/10.2337/diabetes.51.12.3461.
|
| [9] |
Xia W, Li Y, Wang B, et al. Enhanced store—operated calcium entry in platelets is associated with peripheral artery disease in type 2 diabetes. Cell Physiol Biochem. 2015; 37(5):1945-1955. https://doi.org/10.1159/000438555.
|
| [10] |
Voelkers M, Salz M, Herzog N, et al. Orai1 and Stim1 regulate normal and hypertrophic growth in cardiomyocytes. J Mol Cell Cardiol. 2010; 48(6):1329-1334. https://doi.org/10.1016/j.yjmcc.2010.01.020.
|
| [11] |
Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol. 2007; 7(9):690-702. https://doi.org/10.1038/nri2152.
|
| [12] |
Eguchi A, Coleman R, Gresham K, et al. GRK5 is a regulator of fibroblast activation and cardiac fibrosis. Proc Natl Acad Sci U S A. 2021; 118(5):e2012854118. https://doi.org/10.1073/pnas.2012854118.
|
| [13] |
Luo Y, Jiang N, May HI, et al. Cooperative binding of ETS2 and NFAT links Erk1/2 and calcineurin signaling in the pathogenesis of cardiac hypertrophy. Circulation. 2021; 144(1):34-51. https://doi.org/10.1161/circulationaha.120.052384.
|
| [14] |
He X, Wang J, Li M, et al. Eucommia ulmoides Oliv.: ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol. 2014; 151(1):78-92. https://doi.org/10.1016/j.jep.2013.11.023.
|
| [15] |
Li L, Su C, Chen X, et al. Chlorogenic acids in cardiovascular disease: a review of dietary consumption, pharmacology, and pharmacokinetics. J Agric Food Chem. 2020; 68(24):6464-6484. https://doi.org/10.1021/acs.jafc.0c01554.
|
| [16] |
Zhang Y, Lei Y, Yao X, et al. Pinoresinol diglucoside alleviates ischemia/reperfusion—induced brain injury by modulating neuroinflammation and oxidative stress. Chem Biol Drug Des. 2021; 98(6):986-996. https://doi.org/10.1111/cbdd.13956.
|
| [17] |
Luo LF, Wu WH, Zhou YJ, et al. Antihypertensive effect of Eucommia ulmoides Oliv. extracts in spontaneously hypertensive rats. J Ethnopharmacol. 2010; 129(2):238-243. https://doi.org/10.1016/j.jep.2010.03.019.
|
| [18] |
Yuan W, Liang X, Liu YY, et al. Pinoresinol diglucoside ameliorates H/R—induced injury of cardiomyocytes by regulating miR—142—3p and HIF1AN. J Biochem Mol Toxicol. 2022; 36(10):e23175. https://doi.org/10.1002/jbt.23175.
|
| [19] |
Chen Y, Pan R, Zhang J, et al. Pinoresinol diglucoside (PDG) attenuates cardiac hypertrophy via AKT/mTOR/NF—κB signaling in pressure overload—induced rats. J Ethnopharmacol. 2021; 272:113920. https://doi.org/10.1016/j.jep.2021.113920.
|
| [20] |
Li H, Wang X, Mao Y, et al. Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p—AMPK. Cardiovasc Diabetol. 2014; 13:24. https://doi.org/10.1186/1475—2840—13—24.
|
| [21] |
Yang F, Luo G, Liu MN, et al. Network pharmacology and experimental validation to investigate the mechanism of action of Zhilong Huoxue Tongyu Capsule in the prevention and treatment of diabetic cardiomyopathy. PLoS One. 2025; 20(5):e0323745. https://doi.org/10.1371/journal.pone.0323745.
|
| [22] |
Liu M, Wang Y, Deng W, et al. Combining network pharmacology, machine learning, molecular docking and molecular dynamic to explore the mechanism of Chufeng Qingpi Decoction in treating schistosomiasis. Front Cell Infect Microbiol. 2024; 14:1453529. https://doi.org/10.3389/fcimb.2024.1453529.
|
| [23] |
Li C, Wen R, Liu D, et al. Assessment of the potential of Sarcandra glabra (Thunb) Nakai. in treating ethanol—induced gastric ulcer in rats based on metabolomics and network analysis. Front Pharmacol. 2022; 13:810344. https://doi.org/10.3389/fphar.2022.810344.
|
| [24] |
Suriano F, Vieira—Silva S, Falony G, et al. Novel insights into the genetically obese (ob/ob) and diabetic (db/db) mice: two sides of the same coin. Microbiome. 2021; 9(1):147. https://doi.org/10.1186/s40168—021—01097—8.
|
| [25] |
Huang L, Lyu Q, Zheng W, et al. Traditional application and modern pharmacological research of Eucommia ulmoides Oliv..Chin Med. 2021; 16(1):73. https://doi.org/10.1186/s13020—021—00482—7.
|
| [26] |
Paolillo S, Marsico F, Prastaro M, et al. Diabetic cardiomyopathy: definition, diagnosis, and therapeutic implications. Heart Fail Clin. 2019; 15(3):341-347. https://doi.org/10.1016/j.hfc.2019.02.003.
|
| [27] |
Fang T, Wang J, Sun S, et al. JinLiDa Granules alleviates cardiac hypertrophy and inflammation in diabetic cardiomyopathy by regulating TP53. Phytomedicine. 2024; 130:155659. https://doi.org/10.1016/j.phymed.2024.155659.
|
| [28] |
Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018; 122(4):624-638. https://doi.org/10.1161/circresaha.117.311586.
|
| [29] |
Mori J, Patel VB, Abo AO, et al. Angiotensin 1—7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation. Circ Heart Fail. 2014; 7(2):327-339. https://doi.org/10.1161/circheartfailure.113.000672.
|
| [30] |
Su D, Gao Q, Guan L, et al. Downregulation of SOX11 in fetal heart tissue, under hyperglycemic environment, mediates cardiomyocytes apoptosis. J Biochem Mol Toxicol. 2021; 35(1):e22629. https://doi.org/10.1002/jbt.22629.
|
| [31] |
Jubaidi FF, Zainalabidin S, Taib IS, et al. The potential role of flavonoids in ameliorating diabetic cardiomyopathy via alleviation of cardiac oxidative stress, inflammation and apoptosis.Int J Mol Sci. 2021; 22(10):5094. https://doi.org/10.3390/ijms22105094.
|
| [32] |
Sun S, Yang S, Dai M, et al. The effect of Astragalus polysaccharides on attenuation of diabetic cardiomyopathy through inhibiting the extrinsic and intrinsic apoptotic pathways in high glucose—stimulated H9C2 cells. BMC Complement Altern Med. 2017; 17(1):310. https://doi.org/10.1186/s12906—017—1828—7.
|
| [33] |
Li J, Richmond B, Cluntun AA, et al. Cardiac gene therapy treats diabetic cardiomyopathy and lowers blood glucose. JCI Insight. 2023; 8(18):e166713. https://doi.org/10.1172/jci.insight.166713.
|
| [34] |
Huang W, He C, Kim HI, et al. MMP3 as a new target of Danshensu/tetramethylpyrazine derivative for attenuating cardiac fibrosis post—myocardial infarction. Life Sci. 2025; 370:123570. https://doi.org/10.1016/j.lfs.2025.123570.
|
| [35] |
Liu X, Chang Y, Choi S, et al. Blocking store—operated Ca2+ entry to protect HL—1 cardiomyocytes from epirubicin—induced cardiotoxicity. Cells. 2023; 12(5):723. https://doi.org/10.3390/cells12050723.
|
| [36] |
Wu QR, Zheng DL, Liu PM, et al. High glucose induces Drp1—mediated mitochondrial fission via the Orai1 calcium channel to participate in diabetic cardiomyocyte hypertrophy. Cell Death Dis. 2021; 12(2):216. https://doi.org/10.1038/s41419—021—03502—4.
|
| [37] |
Lu T, Zhou D, Gao P, et al. Resveratrol attenuates high glucose—induced endothelial cell apoptosis via mediation of store—operated calcium entry. Mol Cell Biochem. 2018; 442(1—2):73-80. https://doi.org/10.1007/s11010—017—3194—7.
|
| [38] |
Kuo WW, Chung LC, Liu CT, et al. Effects of insulin replacement on cardiac apoptotic and survival pathways in streptozotocin—induced diabetic rats. Cell Biochem Funct. 2009; 27(7):479-487. https://doi.org/10.1002/cbf.1601.
|
| [39] |
Lu Y, Zhao M, Liu JJ, et al. Long—term administration of pyridostigmine attenuates pressure overload—induced cardiac hypertrophy by inhibiting calcineurin signalling. J Cell Mol Med. 2017; 21(9):2106-2116. https://doi.org/10.1111/jcmm.13133.
|
| [40] |
Marthandam AS, Yang JY, Lin WT. Anti—hypertrophic and anti—apoptotic effects of short peptides of potato protein hydrolysate against hyperglycemic condition in cardiomyoblast cells. Biomed Pharmacother. 2018; 107:1667-1673. https://doi.org/10.1016/j.biopha.2018.08.070.
|
PDF
